JP2020516289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516289A5 JP2020516289A5 JP2019555834A JP2019555834A JP2020516289A5 JP 2020516289 A5 JP2020516289 A5 JP 2020516289A5 JP 2019555834 A JP2019555834 A JP 2019555834A JP 2019555834 A JP2019555834 A JP 2019555834A JP 2020516289 A5 JP2020516289 A5 JP 2020516289A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- risk allele
- linkage disequilibrium
- subject
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023121229A JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485077P | 2017-04-13 | 2017-04-13 | |
| US62/485,077 | 2017-04-13 | ||
| PCT/US2018/023266 WO2018190990A1 (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023121229A Division JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516289A JP2020516289A (ja) | 2020-06-11 |
| JP2020516289A5 true JP2020516289A5 (https=) | 2021-04-22 |
| JP7321939B2 JP7321939B2 (ja) | 2023-08-07 |
Family
ID=61911717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555834A Active JP7321939B2 (ja) | 2017-04-13 | 2018-03-20 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2023121229A Active JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A Pending JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023121229A Active JP7557581B2 (ja) | 2017-04-13 | 2023-07-26 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| JP2024158740A Pending JP2024163308A (ja) | 2017-04-13 | 2024-09-13 | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11708415B2 (https=) |
| EP (3) | EP3610041A1 (https=) |
| JP (3) | JP7321939B2 (https=) |
| KR (2) | KR102605045B1 (https=) |
| CN (1) | CN110431240B (https=) |
| AU (3) | AU2018252974B2 (https=) |
| CA (1) | CA3059350A1 (https=) |
| ES (1) | ES3052989T3 (https=) |
| IL (2) | IL269873B2 (https=) |
| MX (2) | MX2019012171A (https=) |
| SG (1) | SG11201909457XA (https=) |
| WO (1) | WO2018190990A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| JP7165618B2 (ja) * | 2019-04-23 | 2022-11-04 | ジェネシスヘルスケア株式会社 | アレルギー性鼻炎のリスクを判定する方法 |
| SG11202111255YA (en) * | 2019-05-01 | 2021-11-29 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| WO2021011614A1 (en) | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| MX2024005769A (es) * | 2021-11-11 | 2024-05-24 | Regeneron Pharma | Tratamiento de la enfermedad pulmonar basado en la estratificacion de puntuacion de riesgo poligenico para la interleucina 33 (il-33). |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| MXPA06004853A (es) | 2003-11-07 | 2006-07-06 | Immunex Corp | Anticuerpos que se aglutinan al receptor 4 de interleucina. |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CN101426518A (zh) * | 2006-01-11 | 2009-05-06 | 艾罗文斯公司 | 用于治疗人类和非-人类灵长类中哮喘的方法和组合物 |
| FR2900817B1 (fr) * | 2006-05-12 | 2008-12-19 | Gambro Lundia Ab | Bandage a usage medical pour un tube implante dans un patient, ainsi que le procede d'application de ce bandage sur la peau d'un patient |
| CN1896275B (zh) * | 2006-06-29 | 2010-04-07 | 四川大学华西医院 | 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101600456A (zh) * | 2006-12-11 | 2009-12-09 | 惠氏公司 | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| WO2010067381A1 (en) * | 2008-12-12 | 2010-06-17 | Decode Genetics Ehf | Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction |
| WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| WO2012113813A1 (en) | 2011-02-23 | 2012-08-30 | F. Hoffmann-La Roche Ag | Antibodies against human il33r and uses thereof |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JP6306588B2 (ja) * | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| AU2013357427B2 (en) * | 2012-12-10 | 2017-08-31 | Universiteit Gent | Novel Interleukin-33 inhibitors |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| WO2014152195A1 (en) * | 2013-03-15 | 2014-09-25 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| BR112016013347B1 (pt) | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| EP3129497B1 (en) * | 2014-04-11 | 2021-09-08 | Novartis AG | Methods of selectively treating asthma using il-13 antagonists |
| NO2785538T3 (https=) | 2014-05-07 | 2018-08-04 | ||
| CN107109494B (zh) * | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| TWI705976B (zh) | 2014-11-10 | 2020-10-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
| CA3246946A1 (en) * | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| CN104531689A (zh) * | 2014-12-12 | 2015-04-22 | 上海交通大学医学院附属新华医院 | 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用 |
| KR102261618B1 (ko) | 2015-03-31 | 2021-06-04 | 메디뮨 리미티드 | 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법 |
| EA201890891A1 (ru) * | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
-
2018
- 2018-03-20 ES ES21162316T patent/ES3052989T3/es active Active
- 2018-03-20 EP EP18716446.2A patent/EP3610041A1/en not_active Withdrawn
- 2018-03-20 CA CA3059350A patent/CA3059350A1/en active Pending
- 2018-03-20 WO PCT/US2018/023266 patent/WO2018190990A1/en not_active Ceased
- 2018-03-20 KR KR1020197030870A patent/KR102605045B1/ko active Active
- 2018-03-20 AU AU2018252974A patent/AU2018252974B2/en active Active
- 2018-03-20 MX MX2019012171A patent/MX2019012171A/es unknown
- 2018-03-20 SG SG11201909457X patent/SG11201909457XA/en unknown
- 2018-03-20 JP JP2019555834A patent/JP7321939B2/ja active Active
- 2018-03-20 EP EP25162154.6A patent/EP4549586A3/en active Pending
- 2018-03-20 CN CN201880018649.2A patent/CN110431240B/zh active Active
- 2018-03-20 KR KR1020237039438A patent/KR102751957B1/ko active Active
- 2018-03-20 IL IL269873A patent/IL269873B2/en unknown
- 2018-03-20 IL IL314591A patent/IL314591A/en unknown
- 2018-03-20 EP EP21162316.0A patent/EP3957752B1/en active Active
-
2019
- 2019-10-10 MX MX2024002689A patent/MX2024002689A/es unknown
- 2019-10-11 US US16/599,709 patent/US11708415B2/en active Active
-
2023
- 2023-07-26 JP JP2023121229A patent/JP7557581B2/ja active Active
-
2024
- 2024-09-13 JP JP2024158740A patent/JP2024163308A/ja active Pending
- 2024-09-30 AU AU2024220212A patent/AU2024220212A1/en active Pending
- 2024-09-30 AU AU2024220214A patent/AU2024220214A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516289A5 (https=) | ||
| Maspero et al. | Type 2 inflammation in asthma and other airway diseases | |
| De la Rica et al. | COVID-19: in the eye of the cytokine storm | |
| Atreya et al. | Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease | |
| Rutgeerts et al. | A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis | |
| Mouthon et al. | Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg–Strauss syndrome) | |
| US11016099B2 (en) | Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers | |
| Peyrin-Biroulet et al. | Early Crohn disease: a proposed definition for use in disease-modification trials | |
| JP6563976B2 (ja) | 可溶性ヒトｓｔ−２抗体およびアッセイ法 | |
| Wright et al. | Cardiovascular comorbidity in rheumatic diseases a focus on heart failure | |
| JP2010516678A5 (https=) | ||
| JP2013500941A5 (https=) | ||
| JP2016511823A5 (https=) | ||
| JP2018535394A5 (https=) | ||
| FI3774897T3 (fi) | Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon | |
| JP2018533557A5 (https=) | ||
| Gaber et al. | Clinical significance of serum interleukin-6 and− 174 G/C promoter polymorphism in Rheumatoid arthritis patients | |
| US10526656B2 (en) | Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers | |
| JP2011184466A5 (https=) | ||
| US10508307B2 (en) | Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers | |
| JP2021532060A5 (https=) | ||
| JP2017519523A (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| Lucendo | Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies | |
| Farrokhi et al. | Mannose-binding lectin mediated complement pathway in autoimmune neurological disorders | |
| Ou et al. | Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn’s disease via fibroblast-specific YAP/TAZ inhibition |